The Mechanisms Underlying the Glucagon-Induced Suppression of Ghrelin Secretion
试验速览
- 阶段
- 3 期
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Changes in satiety scale, total and acylated ghrelin concentrations.
研究概览
简要总结
As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol release in humans. Recently, it has been shown that glucagon induces a remarkable decrease in ghrelin levels. The mechanisms underlying this effect are unclear and the role of changes in glucose, insulin, glucagon-like peptide-1 (GLP-1) and catecholamines are widely discussed. The aim of the present study is to further evaluate the effect of glucagon on ghrelin secretion and the possible role of the above mentioned factors in mediating this effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects > 18 and < 60 years old.
- •Patients with diabetes type 1 should fulfill the following criteria:
- •ICT Insulin therapy was necessary within the first 3 months after diagnosis;
- •HbA1c-Wert < 7%.
排除标准
- •Diabetes type 1 or 2 (for the healthy group).
- •Biochemical evidence of impaired hepatic or renal function.
- •History of cardiovascular disease.
- •Uncontrolled hypertension.
- •Current inflammatory, malignant or psychiatric disease.
- •Pregnancy
研究组 & 干预措施
Glucagon hydrochloride
GlucaGen® 1 mg/1 ml intramuscularly
干预措施: Glucagon hydrochloride (GlucaGen®) (Drug)
Placebo
1 ml NaCl 0.9%
干预措施: NaCl 0.9% (Drug)
结局指标
主要结局
Changes in satiety scale, total and acylated ghrelin concentrations.
时间窗: During 240 min after Glucagon/Placebo administration.
次要结局
- Changes in glucose, insulin and NEFA concentrations.(During 240 min after Glucagon/Placebo administration.)